Concord Drugs Limited (BOM:538965)

Concord Drugs Statistics

Total Valuation

Concord Drugs has a market cap or net worth of INR 1.08 billion. The enterprise value is 1.20 billion.

Market Cap	1.08B
Enterprise Value	1.20B

Important Dates

The next confirmed earnings date is Wednesday, May 27, 2026.

Earnings Date	May 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Concord Drugs has 13.18 million shares outstanding. The number of shares has increased by 11.05% in one year.

Current Share Class	13.18M
Shares Outstanding	13.18M
Shares Change (YoY)	+11.05%
Shares Change (QoQ)	-63.83%
Owned by Insiders (%)	66.79%
Owned by Institutions (%)	n/a
Float	4.38M

Valuation Ratios

The trailing PE ratio is 85.93.

PE Ratio	85.93
Forward PE	n/a
PS Ratio	1.37
PB Ratio	2.22
P/TBV Ratio	2.22
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.44, with an EV/FCF ratio of -15.18.

EV / Earnings	114.12
EV / Sales	1.53
EV / EBITDA	26.44
EV / EBIT	37.78
EV / FCF	-15.18

Financial Position

The company has a current ratio of 2.53, with a Debt / Equity ratio of 0.28.

Current Ratio	2.53
Quick Ratio	1.19
Debt / Equity	0.28
Debt / EBITDA	2.99
Debt / FCF	-1.71
Interest Coverage	1.86

Financial Efficiency

Return on equity (ROE) is 2.55% and return on invested capital (ROIC) is 3.98%.

Return on Equity (ROE)	2.55%
Return on Assets (ROA)	2.84%
Return on Invested Capital (ROIC)	3.98%
Return on Capital Employed (ROCE)	5.92%
Weighted Average Cost of Capital (WACC)	7.71%
Revenue Per Employee	3.15M
Profits Per Employee	42,200
Employee Count	250
Asset Turnover	1.13
Inventory Turnover	2.66

Taxes

In the past 12 months, Concord Drugs has paid 4.18 million in taxes.

Income Tax	4.18M
Effective Tax Rate	28.39%

Stock Price Statistics

The stock price has increased by +155.16% in the last 52 weeks. The beta is 0.60, so Concord Drugs's price volatility has been lower than the market average.

Beta (5Y)	0.60
52-Week Price Change	+155.16%
50-Day Moving Average	78.53
200-Day Moving Average	74.35
Relative Strength Index (RSI)	52.66
Average Volume (20 Days)	4,650

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Concord Drugs had revenue of INR 787.71 million and earned 10.55 million in profits. Earnings per share was 0.95.

Revenue	787.71M
Gross Profit	111.25M
Operating Income	31.87M
Pretax Income	14.73M
Net Income	10.55M
EBITDA	45.54M
EBIT	31.87M
Earnings Per Share (EPS)	0.95

Balance Sheet

The company has 7.51 million in cash and 135.99 million in debt, with a net cash position of -128.49 million or -9.75 per share.

Cash & Cash Equivalents	7.51M
Total Debt	135.99M
Net Cash	-128.49M
Net Cash Per Share	-9.75
Equity (Book Value)	485.14M
Book Value Per Share	98.94
Working Capital	322.44M

Cash Flow

In the last 12 months, operating cash flow was -67.66 million and capital expenditures -11.67 million, giving a free cash flow of -79.33 million.

Operating Cash Flow	-67.66M
Capital Expenditures	-11.67M
Depreciation & Amortization	13.67M
Net Borrowing	-35.93M
Free Cash Flow	-79.33M
FCF Per Share	-6.02

Margins

Gross margin is 14.12%, with operating and profit margins of 4.05% and 1.34%.

Gross Margin	14.12%
Operating Margin	4.05%
Pretax Margin	1.87%
Profit Margin	1.34%
EBITDA Margin	5.78%
EBIT Margin	4.05%
FCF Margin	n/a

Dividends & Yields

Concord Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.05%
Shareholder Yield	-11.05%
Earnings Yield	0.98%
FCF Yield	-7.38%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	4